ECSS
KRYS icon

Eurizon Capital SGR SpA’s Krystal Biotech KRYS Stock Holding History

Eurizon Capital SGR SpA’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$222K Buy
587
+34
+6% +$10.2K ﹤0.01% 726
2026
Q1 		$137K Hold
553
– – ﹤0.01% 819
2025
Q4 		$137K Buy
+553
New +$116K ﹤0.01% 715

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Eurizon Capital SGR SpA's KRYS Position: Q2 2026 in Review

Eurizon Capital SGR SpA increased its Krystal Biotech (KRYS) stake by 6.1% in Q2 2026, buying an estimated $10.2K and bringing the position to 587 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #726.

Eurizon Capital SGR SpA first reported a position in KRYS in Q4 2025 and has held it in 3 quarters since. 422 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Eurizon Capital SGR SpA held 587 shares of Krystal Biotech worth $222K as of Q2 2026.
  • Eurizon Capital SGR SpA bought 34 Krystal Biotech shares in Q2 2026, an estimated $10.2K.
  • Krystal Biotech made up ﹤0.01% of Eurizon Capital SGR SpA's portfolio in Q2 2026, its #726 holding.
  • Eurizon Capital SGR SpA first reported a position in Krystal Biotech in Q4 2025 and has held it in 3 quarters since.
  • 422 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Eurizon Capital SGR SpA's 13F filing for Q2 2026, filed 29 Jul 2026.